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Abstract Overactive bladder (OAB) is a syndrome of urinary
urgency, usually accompanied by frequency, nocturia, and
sometimes urinary urgency incontinence. There are many
guidelines for the OAB treatment which are constructed on a
stepwise fashion starting from the least invasive to the more
invasive therapy. The emergence of third-line therapy (AUA/
SUFU guidelines) has resulted in significant decrease of more
invasive surgery and improved patients’ quality of life. The
aim of a clinical pathway is to improve the quality of care,
reduce risks, increase patient satisfaction, and increase the
efficiency in the use of resources. The available options for
the third-line OAB treatments include intravesical injection of
botulinum toxin A, percutaneous tibial nerve stimulation
(PTNS), and sacral nerve stimulation (SNS). The available
evidence confirms that all three treatment approaches are well
tolerated and effective, although only botulinum toxin type A
(BoNTA) and SNS can achieve nearly a cure of urgency urinary
incontinence (UUI). The choice among the different third-line
treatment depends on patient preference, availability, and local
expertise. The application of these pathways can improve in-
continence care by letting physicians adequately communicate
with patients and select individualized therapy at an early stage
especially for elderly patients.
Keywords Overactivebladder .Clinicalpathways .Third line
treatment . Onabotulinum toxin A . Sacral neuromodulation .
Percutaneous tibial nerve stimulation
Introduction
Idiopathic overactive bladder (I-OAB) is defined by the Inter-
national Continence Society (ICS) as symptom complex of
Burinary urgency that is frequently accompanied by urinary
frequency (voiding eight or more times in a 24-hour period)
and nocturia (awakening two or more times at night to void),
with or without urgency urinary incontinence (UUI), in the
absence of a urinary tract infection or other obvious
pathology^ [1]. Symptoms may or may not be associated with
detrusor overactivity (DO) [2–4]. Patients with neurologic
disorders often experience voiding dysfunction. When this
voiding dysfunction is consistent with OAB, it is termed neu-
rogenic overactive bladder (N-OAB) [5]. OAB is a common
chronic condition with its prevalence increases with age in
both women and men, and it should not be considered as part
of normal aging process [6–8].
OAB has a significant burden for patients and healthcare
providers such as negative impact on the social, physical,
psychological, financial, and sexual aspects of quality of life
but generally do not affect survival [9].
In general, a clinical pathway is a structured method for the
patient-care management of a well-defined group of patients
during a well-defined period of time. A clinical pathway clear-
ly states the goals and key elements of care based on evidence-
based medicine (EBM) guidelines, best practice, and patient
expectations. The aim of a clinical pathway is to improve the
quality of care, reduce risks, increase patient satisfaction, and
increase the efficiency in the use of resources. This includes
facilitating the communication and coordinating roles and
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sequencing the activities of the multidisciplinary care team,
patients, and their relatives. It also requires documenting,
monitoring, and evaluating variances and providing the nec-
essary resources and outcomes.
This article may help to provide a practical clinical pathway
regarding the third-line treatment for the elderly population
who suffer from refractory lower urinary tract symptoms.
The application of these pathways can improve incontinence
care by letting physicians to adequately communicate with
patients and select individualized therapy at early stage espe-
cially for elderly patients. This is a patient-centeric approach
that improves efficacy of treatment and quality of life and
safety. Keeping patients informed of the plan of care and on
schedule improves their compliance and potentially eliminates
unnecessary testing and achieves cost savings. Also, by hav-
ing a clear pathway communicated to the patient can gain
early acceptance of third-line therapies and avoid the high
drop-out noticed with medical therapy.
The treatment of OAB as recommended by the Internation-
al Consultation on Incontinence (ICI) and AUA/SUFU [10••,
11] are as follows:
First-line therapy: First-line treatments include conserva-
tive measures such as adjustment of fluid habits, review
of drug treatment, timed voiding, bladder retraining, and
pelvic floor muscle therapy. Behavioral therapies and ed-
ucation should be offered first; starting antimuscarinic
therapies at the same time as behavior therapies may
prove clinically beneficial. This line should be offered
to all patients.
Second-line therapy: Pharmacotherapy for minimum
3 months with either antimuscarinics (extended-release
preparations should be used instead of immediate-
release preparations when possible) or oral beta-3
adrenoceptor agonist (mirabegron) should be offered
too. Despite the proven efficacy of pharmacotherapy
treatment, it is difficult to predict the response in the in-
dividual patient, the adverse effects, and lack to adher-
ence for long period, especially for elderly Bfrail^ patients
[12, 13], who should be use with caution as they have a
lower therapeutic index and higher adverse effects (AE)
such as dizziness, dry mouth, blurred vision, and consti-
pation and the effects of multiple medications should be
considered [10••]; the elder Bfrail^ can be define as Belder
person who have combining impaired physical activity,
balance, muscle strength, cognition, and nutrition.^
Third-line therapy: Intradetrusor botulinum toxin type A
(BoNTA) and neuromodulation therapies such as sacral
neuromodulation (SNM) or percutaneous tibial nerve
stimulation (PTNS) for carefully selected patients with
severe refractory OAB symptoms or those who are not
respond to or don not tolerate the second-line therapy and
are willing to undergo a surgical procedure [10••].
The AUA/SUFU guidelines state that after attempting to
treat OAB for 4 to 8 weeks with medications, taking the step
towards third-line therapy is worthwhile and justified.
Third-Line OAB Treatment
General Principle
The importance of understanding patient expectations,
goals, and satisfaction is increasingly recognized as an
important element in the decision to treat OAB. For
either I-OAB or neurogenic detrusor overactivity (N-
OAB), eliciting patient perceptions and sharing the best
available evidence with relevant options are important in
achieving patient satisfaction [14•, 15]. Typically, when
the patient goals are defined, outcomes should be cor-
related with relief of symptom(s), patient satisfaction,
and goal achievement expectations as a result of
treatment.
We believe that the approach treatment to the patient with
OAB in the standard step-wise algorithm pathway is reason-
able (Fig. 1), but in some occasions may subject patients to
unnecessary cost and delay in treatment. The general principle
for pharmacotherapy of the elderly patient is to start with a low
dose and increase it slowly, depending on the agent’s pharma-
cokinetics and pharmacodynamics and adverse effects.
Treatments of OAB at early stage may help to improve
patient care and minimize overall use of healthcare re-
sources. There is considerable evidence of delay in diag-
nosis, which may be related to embarrassment, belief that
certain bladder symptoms as normal aging process, and
assumption that will get little benefits with the treatment.
In addition, failure to adhere to medical therapy due to
lack of response or adverse effects of pharmacotherapy
usually leads to frustration and abandoning of medica-
tions. The inadequate follow-up after treatment with poor
communication between patients and physician has been
identified as important factor to non-adherence [16]. It has
been shown that 10 % of patients with OAB do not start
the medication 12 months after prescription [17]. Motiva-
tion of the patient with regular follow-up visits to monitor
treatment effects and adherence may be useful [18].
Patient satisfaction with treatment is directly related
to improvement of symptoms and expectations, which
need adequate follow-up after initial treatment (good
motivation). Discussion of the patient’s goals and expec-
tation before starting treatment should be realistic and
agreed upon by the patient and physician. Patients
should be aware that OAB especially when severe is a
chronic complex condition that can be improved, but is
unlikely to be cured [19].
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Refractory OAB
Refractory OAB could be defined as persistent urgency, fre-
quency, with or without incontinence that remains bothersome
despite adequate behavioral and medical therapy for 8 to
12 weeks with at least one medication administered for 4 to
8 weeks [10••, 11]. However, there is no current consensus on
appropriate definition of such concept neither inclusion of
failure secondary to intolerable side effects [20, 21].
The term Bfailed^ or refractory OAB can be applied if the
patient expectations and satisfaction are not achieved with
second-line OAB treatment due to lack of efficacy or AE.
Physicians should be aware that factors such as psychological
well-being and emotional and sexual health outcomes affect
patient perceptions of the value of treatment, perceived treat-
ment efficacy, and treatment expectations [20, 22, 23].
The reasonable indications for the third-line OAB treat-
ment are as follows: (a) failure of pharmacotherapy of OAB
EVALUATION
History & physical examination; Urine 
Microscopy
+VE UA  
Treat UTI
-VE UA
With OAB symptoms
COUNSELLING:
Address Patient Goals
Benefits & risks of each line
FIRST LINE TREATMENT
Behavioral, PFMT...etc
SECOND LINE TREATMENT
Antimuscarinic +/- 3 agonist
RE-EVALUATE
May need specialized testing: Urinary 
Ultrasound, Cystoscopy, Urodynamic Study
THIRD LINE TREATMENT
Intradetrusor 
onabotulinumtoxin
Sacral 
Neuromodulation
PTNS
(Percutaneous tibial nerve 
stimulation)
ACHIEVEMENT 
OF PATIENT 
GOALS
FOLLOW UP/ 
Efficacy 
&Adverse Effects
Fig. 1 Algorithm clinical pathway for initial management of OAB treatment. It should take 4–8 weeks to reach third-line treatment
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due to lack of efficacy and loss of efficacy; (b) intolerable side
effect; (c) contraindications to pharmacotherapy initiation; (d)
inability to achieve patient’s expectations by dose titration,
switching medications to different anti-muscarinic or B3 ago-
nist drug. The theoretical benefits of extended release
antimuscarinic medications are not well established in elderly
population as most of clinical trials had limited number of
patients above 65 years of age and frail elderly [24, 25].
Re-evaluation of Patients with Refractory OAB
Although OAB can be diagnosed by the patient symptoms, re-
fractory OAB (R-OAB) patients require a basic assessment in
order to exclude any other underlying causes for lower urinary
tract dysfunction before the third-line OAB treatment which can
be corrected. For example, bladder outlet obstruction (BOO) in
men with BPH or women who have history of anti-incontinence
surgery should be excluded since BOO is a known cause for
OAB symptoms. Full detailed history and examinations includ-
ing neurological and urogyncological examination should be
performed. Clean catch urine should be sent for analysis and
culture; significant post void residual urine should also excluded
by ultrasound or catheterization. Patients who have high residual
urine volumes have higher risk of retention following BoNTA
injections. Simple dairy for frequency/volume is useful to docu-
ment and support the diagnosis of OAB and exclude other
causes of urinary symptoms such as nocturnal polyuria.
Most R-OAB patients require functional and anatomical
studies of the lower urinary tract. Urodynamic or better
videourodynamic study is essential to make an accurate diag-
nosis specially to rule out neurogenic dysfunction prior to get
on more invasive or perhaps irreversible therapy.
Cystourethroscopy could be helpful for many elderly pa-
tients with R-OAB especially those with hematuria and pain-
ful bladder syndrome to exclude any other causes for the
LUTS such as a bladder tumor or calculus.
Treatment approach in the elderly depends on the patient’s
goals, social setting, and the mental status of the patient.
Botulinum Toxin A (BoNTA)
BoNTA have been studied as intradetrusor injection for the
treatment of detrusor overactivity since 2000 [26]. Although
the mechanism of action of BoNTA in urinary bladder has
already described in details [27], new information becomes
available every year. It was approved by the US FDA for
use in adults with overactive bladder in January 2013 and by
European Union in 2011.
There are many publications that provide a good useful sum-
mary for the use and the effectiveness of BoNTA in the manage-
ment of OAB and urgency incontinence [28, 29•]. The level of
evidence of effectiveness continues to build with time. Such
randomized, controlled studies have proven that BoNTA
100 U was well tolerated and produced significant clinical im-
provements in all OAB symptoms, patient-reported outcome,
and quality of life (QoL) in patients inadequately managed by
anticholinergics [30–32]. Other interesting evidence of random-
ized controlled trial on BoNTAvs placebo is inmale patient with
refractory OAB; although it did not reach significant statistical
results, but it showed improvement of daily frequency [33].
Published reviews showed the evidence of BoNTA injec-
tion in the management of N-OAB due to multiple sclerosis
and spinal cord injury. The efficacy of treatment reach 75–
90 %, but training for clean intermittent self-catheterization
is mandatory before starting treatment [3]. A systematic re-
view of BoNTA for both N-OAB and I-OAB supported a level
A recommendation for its use in these patients [34]. The effi-
cacy of BoNTA that has been investigated using patient ex-
pectations and satisfactions was found to have high patient-
reported outcome especially with repeated treatments [4].
According to the AUA guidelines for the available evi-
dence on BoNTA in OAB, clinician may offer intradetrusor
Bonita 100 U as third-line OAB treatment [10••], while
NICE guidelines recommend that 200 U should be used,
unless the woman is concerned about retention and accepted
lower success rate, in which case 100 U is acceptable [35].
We developed clinical pathway for intradetrusor BoNTA in-
jection for OAB in general, helping the clinician and the
patient as guidance and for motivations and to increase the
success rate for treatment (Fig. 2). The cost-effectiveness has
been studied between BoNTA with supportive care versus
supportive care alone. It confirmed that BoNTA with sup-
portive care is cost effective with 100 % probability [36].
Counselling and Adverse Outcomes
It is important that patients should be counseled about the risks
and benefits of BoNTA injections, which include urinary re-
tention and urinary tract infections which usually due to in-
complete voiding. Such retention is usually temporary which
may require an indwelling catheter or the need to self-
intermittent catheterization temporarily. Patients treated with
BoNTA have approximately ninefold increased risk of a post-
void residual complication, such as urinary retention [37]. In
phase 3 study when a dose of 100 U is used, retention requir-
ing catheterization was about 5 % [38]. A more helpful evi-
dence to use in counselling is that at 1 month post-BoNTA
injection, about one in four patients will have high residual
urine [39]. The patient must be able and willing to return for
frequent post voiding residual urine volume evaluation and to
perform self-catheterization if necessary.
The patient should be aware that the effects of BoNTA
injection have been shown to last approximately 6–9 months,
so the patients may require repeat injections to continue their
therapeutic benefits.
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BoNTA injection should not be performed in case of positive
urinalysis and culture for urinary tract infection (UTI). In such
case, the UTI should be treated and the injection postponed.
While the use of antibiotics is not indicatedwith cystoscopy in
normal patients, it can be used in cases with voiding dysfunction.
We use routinely prophylaxis antibiotics in the form of ciproflox-
acin for 5 days, starting 2 days prior to BoNTA injection.
Procedure Considerations
BoNTA injection into the bladder wall was originally de-
scribed by using a rigid cystoscopy and an endoscopic needle
to inject 1 mL just beneath the detrusor mucosa at 20–30 sites
sparing the trigone [40]. Later, the technique was changed
using a flexible cystoscopy [41].
We usually offer a minimally invasive technique which
was performed by instillation of 20–40 mL of 2 % lidocaine
into the bladder through a urethral catheter 15–20 min prior to
cystoscopy [42, 43]. Oral mild anxiolytic agent and pain killer
are taken 1 h prior to the procedure. Therefore, BoNTA injec-
tion can be performed in the office with either a rigid or flex-
ible cystoscopy, depending on surgeon’s preference. For treat-
ment of patients with refractory I-OAB, we inject
intradetrusor at 20 sites, sparing the trigone, with 100 U of
BotoxR diluted in 10 mL normal saline solution without pre-
servative at 0.5 mL/site.
INDICATION
OAB (I-OAB or N-OAB) 
with failed or inadequate 
controlled (conservative 
therapies & 2 different 
medications) for 6-8 weeks
Accept & able to perform 
CIC.
CLINICAL PATHWAY
Intradetrusor 
onabotulinumtoxinA
(BOTOX)R
Bladder instillation
Lidocaine 2% 20-30mL      
instilled via urethral catheter 
(15-20min)
COUNSELLING
Agent indication.
Proposal benefits.
Mode of administration.
Delayed effect 1-2 
weeks.
Duration of effect 6-9 
months.
Complications: UTI, 
transient hematuria, 
dysuria, retention and 
possible CIC.
Advice to bring a person 
+ve UA
Treat UTI
PATIENT PREPARTION
Ciprofloxacin TAB 500mg or 250 
mg BID x 5days (start 2 days prior 
injection).
Anxiolytic & Pain killer medication 
(Day of injection, prior to arrival)
SECOND VISIT
EXCULDE 
UTI
UA/UC
I-OAB
100 U
Dilute in10ml NS 
(without preservative)
½ ml/site = 20 Bladder Emptying
(Void or Catheter)
Counsel& discharge home
N-OAB
200 U
Dilute in20ml NS 
(without preservative)
1 ml/site = 20
FOLLOW-UP
(2-4 weeks after injection).
Check for symptoms, Urinalysis & residual urine (bladder 
scan)
FIRST VIST
THIRD VISIT
Fig. 2 Algorithm for Botox injection
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Post-Procedure Follow-up
The patient must be monitored until void urinations are nor-
mal. After the first injection, a patient must be seen 2 to
4 weeks following the injection, in order to evaluate the treat-
ment’s efficacy. This evaluation involved a urinary diary, post-
void residual urine measurement, and urinalysis. A post-void
residual greater than 200 mL and/or symptomatic must be
counseled about the use of self-catheterization. A repeated
injection can be indicated when the clinical benefit of the
preceding injection wears off (typically after a period of 6 to
9 months). In all cases, a delay of 3 months must be respected
between each injection [10••, 12].
Neuromodulation
Neuromodulation techniques have been applied to the sacral
nerve roots or their more distal branches like pudendal and
posterior tibial. There are essentially two types of stimulation
that can be used for neuromodulation.
The first is central/high frequency stimulation (sacral nerve
stimulation) that uses electrodes which were inserted at the
level of the third sacral nerve (S3), which is connected to the
implantable pulse generator. The second one is peripheral/low
frequency stimulation to activate inhibitory pathways in the
spinal cord and inhibit detrusor contraction (percutaneous tib-
ial nerve stimulation).
SNM is FDA-approved since 1997 for urinary frequency
and urgency, and idiopathic non-obstructive urinary retention.
Since then, the acceptance and use of SNM have been grow-
ing [44].
PTNS and SNM are other options as third-line treatment
that may be offered to selected patient with refractory OAB
[10••]. Both are neuromodulatory therapies presumed to im-
prove or restore normal control of an imbalanced voiding
reflex by affecting the central afferents [45].
Sacral Neuromodulation
Patient Selection
Patient selection has played an important role on the success
rate of SNM. In one study, a success rate of 64 % at 2 years
was demonstrated in patients with I-OAB, while all patients
withN-OABwho responded initially relapsedwithin 2months
[46]. Although it is controversial, the role of SNM in patients
with neurogenic bladder was also investigated and success
rates were similar to those in patients with I-OAB [47, 48].
Poor results have been reported in elderly cognitively im-
paired patients and patients with spinal cord injuries [49].
Failure of pharmacotherapy does not appear to indicate a poor
response to SNM [46].
Patients with refractory OAB and non-obstructive urinary
retention are considered suitable for SNM once they have
failed or could not tolerate more conservative treatments [50,
51]. Patients must be cognitively capable of optimizing their
device settings and compliant with the long-term treatment
protocols (Fig. 3).
However, there is still significant variability in use accord-
ing to a standardized treatment algorithm for urinary
dysfunction.
Procedure Considerations
SNM requires a preliminary, percutaneous nerve evaluation
(PNE), a screening stimulation test that is perform to assess
the clinical effect and the integrity of sacral nerve.
Such test help the patient and physician to decide whether
the benefits of permanent implantable pulse generator (IPG)
implantation is worthy, evaluating the benefits, risks, and costs
of the therapy.
There are two approaches for stimulation test, PNE or stage
one out of two-staged implanation.
PNE
The PNE test uses a temporary test lead placed into the
S3 foramen and connected to an external pulse genera-
tor (EPG). The procedure is usually performed in an
outpatient setting under local anesthesia and prone po-
sition. The procedure is done by stimulating the S3
sacral nerves bilaterally and the side prompting the de-
sirable response and comfort for the patient is selected
for the temporary lead insertion. The patient’s electrode
will be connected to an external pulse generator that
gives the patient the ability to control the stimulation
intensity. The patient is discharged home with 5–7-day
voiding diary.
Based on the patient’s subjective experience and the objective
data obtained from the voiding diary, a final decision can bemade
to proceed or not with permanent implantation. If the patient had
the desired response, he/she usually will undergo the permanent
implantation of the tined lead and IPG, i.e., full implantation. On
the other hand, if they do not respond to PNE and there is a
question about wire migration, they may have an excellent out-
come when they undergo two-staged implantation [52].
Complications such as migration of the temporary lead or
failure of this test help to identify patients who will respond to
permanent SNS leading to the development of a two-stage
implant technique [53].
Two-Staged Procedure
If the patient is not a candidate for test stimulation or did not
respond to the outpatient PNE test, stimulationmay be performed
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in the operating room (OR) using the tined lead. In fact, the two-
stage procedure decreases the technical-related test failure.
The advantage of this procedure is that the same responses
should be obtained once the external generator is replaced by
the permanent IPG as the lead site does not change. The per-
manent tined lead has self-anchoring tines that reduce the risk
of migration.
This procedure extends the test periods of up to 2–4 weeks.
If the patient has a good response during the test, the present
lead is then connected to an IPG.
Due to the decreased risk of migration and the longer test
duration, this test has a higher response rate [44, 47, 54].
The choice of PNE or first stage testing depends on patient’s
and physician’s preference. Postoperatively, the IPG will be
VOIDING DAIRY
(3 DAYS as base line)
FIRST VIST
COUNSELLING&CONSENT
SECOND VISIT
PNE/ Test procedurePNE STAGE ONE
Office-base
Stimulation test
(Bilateral, temporary lead test)
Operating room-based
Stimulation test
(Unilateral, permanent lead test)
Temporary 
EPG
THIRD VISIT
SUCCESS & POSITIVE RESPONSE
FULL IMPLANT
(Consent/ Book for operation)
FOURTH VISIT
Procedure day
Four programs set / 1program each week
Follow up 4 weeks
Set up the preferred program
Lead & IPG
(FOR ONE SATGE)
IPG
(FOR TWO STAGE)
No/Poor Response or
Complications
Remove Lead& Re-evaluate
CLINICAL PATHWAY
Sacral
Neuromodulation
(INTERSTIM R)
Sacral Neuromodulation 
is most appropriate for:
Severe refractory OAB.
Desire an alternative to 
medication due to side-
effects or lack of 
efficacy
Sacral Neuromodulation is not
appropriate for patients:
Noncompliant.
Experience primarily stress incontinence
unable to operate the neuromodulation 
system
not appropriate candidates for surgery
Safety & effectiveness not been 
established for (Pregnancy, pediatric <16).
May need MRI (except Head MRI)
Counselling & Consenting
Possible complications: pain at the 
stimulator site or lead site, lead 
migration, infection/irritation, electric 
shock and need for surgical revision.
Patients should be well-informed 
about the limitations of using MRI in 
the future.
Fig. 3 Algorithm for SNM in OAB
Curr Bladder Dysfunct Rep
Author's personal copy
turned on and programming the SNM with different settings.
The patient is taught to set the unit at a comfortable setting at
which the stimulation can be felt but it is not painful and ad-
vised to try different programs to control symptoms [55•].
Percutanous Tibial Nerve Stimulation
PTNS is a peripheral neuromodulation that may be of-
fered by Stoller [56], to nearly any patient with OAB
who has not achieved their treatment goal with medica-
tion, excluding those with a pacemaker and who are
pregnant [10••]. The elderly, the frail, patients with
non-neurogenic detrusor overactivity, those with milder
symptoms or partial responders, and patients with med-
ication adverse effects are all excellent candidates for
PTNS.
PTNS is postulated to achieve detrusor inhibition by
acute electrical stimulation of afferent somatic sacral
nerve fibers. The rational for this treatment modality is
based on the presence of spinal inhibitory systems that
are capable of interrupting a detrusor contraction. Inhi-
bition can be achieved by electrical stimulation of the
pelvic nerve afferent sensory fibers in the pudendal
nerve and muscle afferents from the limbs [57, 58].
Most of these afferent somatic fibers reach the spinal
cord via the sacral spinal nerves and dorsal roots of
the sacral nerves.
AUA/SUFU guidelines recommend PTNS as a third-line
therapy for highly motivated patients who are willing to com-
ply with the frequent office visits required [10••]. PTNS may
be better for those with less refractory, mild tomoderate symp-
toms. PTNS treatment needs up to 3 months to determine
success and, if so, 12 to 18 sessions and visits to the doctor’s
office annually to maintain benefit, each session lasts 30 min
once weekly as common protocol that is used in clinical prac-
tice [59–61].
Several studies have been published evaluating the effects
of PTNS on OAB [56, 62]. PTNS was found to be effective in
reducing urinary frequency, incontinence episodes, and
detrusor overactivity in 37–100 % of patients with OAB
[63••].
Improvements are reported not only in OAB symptoms but
also in urodynamic observations such as reduction of detrusor
overactivity, increase of the cystometric capacity, and of the
threshold of appearance of involuntary detrusor contractions
[59].
There is a lot of data that support the efficacy and safety of
PTNS which strongly and notably reflect what one sees in
clinical practice [64]. Durability of effectiveness of PTNS
has been demonstrated after 12 and 36 months of therapy with
valuable long-term treatment option to sustain clinically sig-
nificant OAB symptom control [60, 65].
Conclusion
The evidence of the third-line OAB treatment continue to
develop which make the guidelines and clinical pathways
provide more solid base recommendations where optimal
management can lead to improvement in the patient outcomes
and QoL.
When it comes to third-line therapy, the patient should be in
the center of decision making. Treatment success is usually
based on patient expectations. Communicating with and
explaining all appropriate options to the patient, based on dif-
fering efficacy and AE profile of the treatments available for
OAB, as well as eliciting patient input, can enhance outcome.
Most published researches on the management of OAB
have been focused on which treatment is more effective, but
may be should look on what is the best treatment option avail-
able for each patient. Eventually, patients do not necessarily
choose the more effective treatment, rather the best one that fit
their needs, and this remains one of their fundamental rights.
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